Tejashri Purohit-Sheth

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Acute Myeloid Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Mona Elmacken, Helkha Peredo-Pinto, Cong Wang, Zhenzhen Xu, Million A Tegenge, Adnan A Jaigirdar, Marc R Theoret, Tejashri Purohit-Sheth, Yvette L Kasamon
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Poornima Sharma, Yvette L Kasamon, Xue Lin, Zhenzhen Xu, Marc R Theoret, Tejashri Purohit-Sheth
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)